FDA Inspection 1204421 — NUVISAN GmbH
The FDA completed an inspection of NUVISAN GmbH on April 26, 2023 in Gauting. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- April 26, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Gauting (Germany)
Additional Details
Clinical BA/BE